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Maintenance of cellular homeostasis and xenobiotic
detoxification is mediated by 19 human UDP-glucu-
ronosyltransferase enzymes (UGTs) encoded by ten
genes that comprise the glucuronidation pathway.
Deep RNA sequencing ofmajormetabolic organs ex-
poses a substantial expansion of the UGT transcrip-
tome by alternative splicing, with variants represent-
ing 20% to 60% of canonical transcript expression.
Nearly a fifth of expressed variants comprise in-
frame sequences that may create distinct structural
and functional features. Follow-up cell-based assays
reveal biological functions for these alternative UGT
proteins. Some isoforms were found to inhibit or
induce inactivation of drugs and steroids in addition
to perturbing global cell metabolism (energy, amino
acids, nucleotides), cell adhesion, and proliferation.
This work highlights the biological relevance of alter-
native UGT expression, which we propose increases
protein diversity through the evolution of metabolic
regulators from specific enzymes.
INTRODUCTION
Human glycosyltransferases utilize different sugar nucleotide
donors to regulate a wide variety of cellular processes (Breton
et al., 2012; De Bruyn et al., 2015; Guillemette et al., 2004; Little
et al., 2004; Rowland et al., 2013). One large family of mem-
brane-associated uridine diphospho-glucuronosyltransferases
(UGTs) employs uridine diphospho-glucuronic acid (UDPGA) to
conjugate a variety of small-molecule acceptors and catalyze
the most important metabolic pathway for the human body’s
elimination of both endogenous and exogenous lipophilic mole-
cules. These ER resident type I membrane proteins transfer the
sugar moiety of the co-substrate UDPGA to the nucleophilic
functional group of their substrates to promote, in most cases,
their inactivation and elimination. Glucuronidation affects the114 Cell Reports 17, 114–124, September 27, 2016 ª 2016 The Auth
This is an open access article under the CC BY-NC-ND license (http://bioactivity and bioavailability of harmful xenobiotics, chemicals,
and drugs from food, the environment, or pharmacological
treatments. In parallel, glucuronidation maintains the homeo-
stasis of the heme breakdown product bilirubin, multiple endog-
enous hormones, secondary metabolites, and other endobiotics
(Bock, 2015; Guillemette, 2003; Radominska-Pandya et al.,
1999; Wells et al., 2004).
In humans, ten genes encode 19 canonical UGT enzymes
(isoform 1s [i1s]) that display remarkable plasticity. For example,
a single UGT1 gene on chromosome 2q37 encodes nine
UGT1A enzymes through usage of individual alternative pro-
moters and first exons, whereas ten UGT2 enzymes (three
UGT2A and seven UGT2B enzymes) are synthesized from nine
independent genes clustered on chromosome 4q13 (Mackenzie
et al., 2005). Although amino acid sequences among UGTs are
highly similar, substrate specificity is dictated by the slightly
more divergent first (UGT1) or first/second (UGT2) exons that
encode the N-terminal half of each enzyme. UGTs are found in
nearly all human tissues and display tissue- and cell-type-spe-
cific expression, but they are most abundant in metabolically
highly active organs such as the liver, kidney, and intestine
(Court et al., 2012; Margaillan et al., 2015a, 2015b; Rowland
et al., 2013).
Alternative splicing (AS) is a key mechanism in the control
of gene expression, transcriptomes, and protein diversity,
with over 90% of human multi-exon genes undergoing AS
regulation before forming mature transcript isoforms (Wang
et al., 2008). The important contributions of AS to an individ-
ual’s response to endogenous and exogenous molecules,
including drugs, and the link to various human diseases
are emerging but remain largely unknown (Gamazon and
Stranger, 2014; Garcia-Blanco et al., 2004; Oltean and Bates,
2014). Our recent work established that AS expands the cod-
ing capacity of human UGTs, allowing over 180 canonical and
alternative UGT transcripts in various tissues involved in drug
metabolism as well as hormone-dependent tissues (Touran-
cheau et al., 2016). Thus, a large genetic diversity character-
izes the transcriptome landscape of human UGTs and implies
a functional diversification of the UGT proteome that remains
unexplored.ors.
creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Profiling the UGT Transcriptome and Characterization of
UGT Isoforms: An Overview of the Experimental Design
The UGT transcriptome in the main drug metabolizing organs (nine or more
samples per tissue) was quantified by RNA-seq after a targeted capture step.
The complete human UGT sequence annotation (Tourancheau et al., 2016)
enabled precise mapping of reads to canonical and alternative transcripts.
Expression and functional analysis of mRNA variants and predicted protein
isoforms were conducted by multiple approaches.
Figure 2. Tissue-Specific Expression of Canonical and Alternative
UGT Transcripts
(A and B) Venn diagrams showing the large diversity in expression patterns
between tissues (A) and between healthy and tumor tissues (B). The total
numbers of canonical (v1) UGTs and alternative variants (alt) are given for each
tissue. The values in the Venn diagrams represent the number of alternative
transcripts (alt) expressed above 600 fragments per kilobase of transcript per
million mapped reads in CaptureSeq.
(C) Average quantitative expression of alternative transcripts in healthy and
tumor tissues. Total expression of alternative transcripts relative to total v1
expression in each tissue is represented.
See also Figure S1.In this study, we applied targeted next-generation RNA seq-
uencing (CaptureSeq) (Clark et al., 2015; Mercer et al., 2011) to
quantify the UGT transcriptome and expression of alternative
transcripts in the liver, kidney, and gastrointestinal tissues,
which are most relevant to the metabolic functions of this
crucial enzymatic pathway. We further addressed tissue-spe-
cific protein expression as well as the function of selected
UGT isoforms where in-frame sequences have been introduced
using cell-based assays combined with untargeted metabolo-
mics (Figure 1). Our findings reveal a complex expression
pattern of UGT alternative variants and distinct functional
properties, including antagonizing and inducing UGT trans-
ferase function, likely through protein-protein interaction, while
inducing substantial rewiring of cell metabolism that affects
cellular behavior.RESULTS
AS Contributes to Quantitative Profiles of the UGT
Transcriptome in Human Metabolic Tissues
A quantitative transcriptome analysis of all ten human UGT1 and
UGT2 genes was conducted in pooled samples of normal liver,
kidney, and intestine/colon tissues as well as in tumors origi-
nating from the kidney and the intestine/colon. A CaptureSeq
approach was used to achieve sufficient sequencing depth
and ensure the fullest coverage of alternative UGT variants.
Reads were mapped to the human genome sequence (hg19)
complemented with the recently published comprehensive hu-
man UGT transcriptome (Tourancheau et al., 2016; Figure 1).
The data revealed that AS contributes substantially to the UGT
transcriptome landscape, affecting each expressed UGT1 and
UGT2 gene in a tissue-specific manner, and the AS products
are significantly altered in neoplastic tissues (Figures 2A and
2B). Alternatively spliced species were abundant in normal tis-
sues, representing an average of 19%, 24%, and 34% of the
total UGT expression in the liver, intestine/colon, and kidney,
respectively (Figure 2C). In intestine/colon and kidney tumor
tissues, these levels were strikingly elevated to an average ofCell Reports 17, 114–124, September 27, 2016 115
Figure 3. Structural Organization of UGTEn-
zymes and Alternative Isoforms
(A) Schematic of functional domains and structural
organization of UGT enzymes in the ER. The bulk
of the substrate-binding (red) and co-substrate-
binding (blue) domains lies on the luminal side
of the ER. The transmembrane domain (gray
segment) positions the positively charged tail
(orange, ++) on the cytoplasmic side of the ER.
N-term, N-terminal; C-term, C-terminal.
(B) Relative quantification of alternative UGT levels
classified on the basis of truncated regions and
inclusion of sequences predicted from alternative
transcript expression levels.33% and 61%, respectively. Changes in liver cancer could not
be assessed because of the lack of availability of hepatic tumors.
The abundance and tissue-specific expression of several alter-
native transcripts supports a physiologically relevant role in the
surveyed tissues.
Diverse Structural Features of Alternative UGT Isoforms
A common structural organization is shared by the 19 known
human UGT1 and UGT2 enzymes, each encoded by a canoni-
cal mRNA variant, v1. An N-terminal signal peptide and a C-ter-
minal transmembrane region direct the substrate and UDPGA
co-substrate-binding domains and catalytic site of eachmature
protein to the luminal side of the ER (Figure 3A). Based on these
structural features, 164 expressed non-v1 alternative tran-
scripts were classified into five categories (Figure 3B). Nearly
half of the expressed alternative UGT variants lacked a seq-
uence encoding the substrate-binding domain (N-terminal),
frequently because of truncation or skipping of exon 1, and
this alteration was especially frequent amongUGT2 transcripts.
In the absence of the N-terminal substrate-binding domain, the
encoded proteins would be expected to lack transferase activ-
ity. Another prominently expressed class of variants that con-
stituted over one-third of alternative variants lacked part or all
of the exons encoding the C-terminal co-substrate domain.
Remarkably, over 20% of the expressed variants comprised
introduction of in-frame sequences. The domain organization
and sequences of the putative isoforms imply that several
may have different subcellular distribution, substrate speci-
ficity, or catalytic activity and thus could have altered biological
functions.
Functional Diversity of Selected Alternate UGTs
Containing In-Frame Sequences
Shorter UGT1 Isoforms with an Alternative C-terminal
Sequence Have Antagonistic Functions
A single UGT1 locus encodes half of the human UGT enzymes;
i.e., nine UGT1A enzymes. It is well established that mature
transcripts encoding each UGT1A enzyme include only one116 Cell Reports 17, 114–124, September 27, 2016of the different UGT1 exon 1 sequences
associated with four downstream exons
common to all UGT1A enzymes (i1s). A
splicing event involving the use of an
alternative 30-terminal exon (exon 5b) generates three cate-
gories of UGT1 transcripts, namely the canonical v1 (exon
5a) and alternative v2 (exon 5b) and v3 (exons 5b and 5a) (Fig-
ure 4A). Our CaptureSeq data and those of an independent
RNA sequencing (RNA-seq) study revealed significant expres-
sion of v2/v3, with these transcripts representing between 9%
and 20% of canonical UGT1A transcripts in normal tissues
and high interindividual variability (Figures S1A and S1B). In
kidney and intestine/colon tumor tissues, v2/v3 constituted
between 19% and 23% of UGT1A_v1 expression. Because
of a stop codon in exon 5b, the alternative v2/v3 variants
both encode shorter, 45-kDa isoform 2 proteins (i2s) lacking
the C-terminal 99 amino acid residues encoded by exon 5a
that comprise the membrane-spanning domain and the short
cytosolic charged tail. In alternate UGT1A_i2 proteins, this
sequence is replaced by a charged ten-residue C-terminal
sequence not found in any other human proteins. The func-
tions of i2s were studied in the HEK293 human embryonic kid-
ney cell line, in which endogenous UGTs are not detected.
UGT1A1_i2 had a remarkably long half-life compared with
that of UGT1A1_i1 (11.6 hr versus 1.3 hr), whereas co-expres-
sion of the two isoforms did not alter their respective half-lives
(Figure 4B). In situ enzymatic assays in intact cells supported
the notion that UGT1A1_i2 lacks transferase activity; rather, it
has an antagonist role leading to a significant reduction in UG-
T1A1_i1-mediated glucuronidation of the anti-cancer agent
SN-38 (the active metabolite of irinotecan, 73.5%, p <
0.001) and the endogenous substrate estradiol (E2, –75%,
p < 0.001) (Figure 4C). These antagonistic effects of i2 are
consistent with the co-immunoprecipitation (IP) of UGT1A_i2
with UGT1A_i1 (Figure 4D) as well as with the co-localization
of both isoforms in the ER as assessed by immunofluores-
cence (IF; Figure 4E) and in cells of human tissues by immuno-
histochemistry (IHC; Figure 4F). The data also indicated that
UGT1A proteins are distributed in other subcellular compart-
ments (Figure S2). In colon tissues, i1 and i2 co-localized at
surface epithelial cells and in intestinal gland (crypt) cells,
whereas in liver tissues, the two isoforms co-localized in
hepatocytes.
Figure 4. Functional Characterization of Alternate UGT1A_i2
(A) The nine well characterized UGT1A_v1 transcripts are produced from splicing of alternative exons 1 to the common exons 2–5a (blue lines) at the single UGT1
locus and encode the nine UGT1A_i1 enzymes. The UGT1A_v2 and UGT1A_v3 transcripts (nine of each type) arise from the use of alternative exon 5b without or
with exon 5a, respectively (green lines). UGT1A_v2 and _v3 transcripts encode the same nine UGT1A_i2 proteins because exon 5b includes a stop codon.
UGT1A_i2 and UGT1A_i1 are distinguishable by their divergent C termini. The UGT1A_i2-specific antibody is directed toward the unique i2 amino acid sequence
(green box). The domains are organized as in Figure 3A.
(legend continued on next page)
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AUGT2B7 Isoformwith a Spacer DomainEnhancesDrug
Inactivation and Provokes Remodeling of Cellular
Metabolism and Phenotypic Changes
An alternative full-length UGT2B7_n4 transcript, confirmed by
PCR analysis as containing an introduced sequence, exon 2b
(Figure S3A), encodes an alternate UGT2B7 protein termed iso-
form 8 (UGT2B7_i8) that has a unique 32-residue in-frame inter-
nal region residing at the interface between the N-terminal sub-
strate-binding domain and the C-terminal co-substrate–binding
domain (Figure 5A). CaptureSeq data analysis revealed that
expression of exon 2b-containing transcripts in three pools of
three liver samples was low compared with the canonical tran-
script (Figure S1C). However, the analysis of an independent
RNA-seq dataset derived from 18 different individuals indicated
that the UGT2B7_i8-encoding transcript represented up to 75%
of the canonical UGT2B7 transcripts with an average coeff-
icient of variation of 350% (Figure S1D). Similar patterns of
expression were noted in the kidney, with a greater proportion
of UGT2B7_i8-encoding transcript in kidney tumors relative to
the canonical transcript. The encoded UGT2B7_i8 had a signifi-
cant half-life of 6 hr that was not affected when co-expressed
with the i1 protein, which has a half-life of 12 hr (Figure S3B).
Expression of the encoded i8 protein along with UGT2B7 in hu-
man liver was further established in hepatocytes using an i8-spe-
cific antibody, supporting the expression data of the alternative
isoform and its partial co-localization with UGT2B7_i1 (Fig-
ure 5B). Staining was also observed in smooth muscle cells of
hepatic arteries as well as in the same structures of esophageal,
breast, uterine, testicular, and skeletal muscle tissues (data not
shown), suggesting a potential unique cell type-specific expres-
sion of UGT2B7_i8 that deserves further investigation. Endoge-
nous alternate protein expression was also corroborated by
the detection of peptides specific to the sequence encoded by
exon 2b in human liver samples using a targeted mass spec-
trometry (MS) approach (Figure S4).
UGT-negative (HEK293) and UGT-positive (HepG2) cell
models were established to study the cellular functions of this
UGT2B7 isoform and to reproduce the expression observed in
tissues (i8 < i1). We could not detect the formation of glucuronide
from zidovudine (AZT), the probe substrate of the UGT2B7
enzyme, in UGT2B7_i8-expressing HEK293 cells. However,
the co-expression of UGT2B7_i8 and UGT2B7_i1 induced 1.3-
and 2.1-fold increases in the formation of the glucuronide in
HEK293 and HepG2 cells, respectively, implying a UGT-acti-
vating function (Figure 5C). The potential of UGT2B7_i8 and(B) UGT1A_i2s have a longer protein half-life compared with UGT1A_i1. Top: pro
measured at different times after treatment with cycloheximide using a pan-UGT1
the UGT1A protein level is expressed as a function of time after cycloheximide tr
(C) The HEK293 cell models (UGT-negative) were developed to express UGT1A
curonidation of SN-38 and E2 by UGT1A1_i1 is impaired by the co-expression of U
glucuronidation of these substrates. Activity is normalized to the UGT1A1_i1 leve
(D) Interactions between UGT1A_i1 and i2. IP of i1 from HEK cell lysates with the s
i1 and i2 protein mobility and detection.
(E) Endogenous UGT1A_i1 and i2 co-localize in the ER of colorectal cancer HT11
intensity profiles are given for cross-sections (dashed lines). See also Figure S2
including the ER. Scale bars, 10 mm.
(F) Immunohistochemical investigation of UGT1A_i1 and i2 in consecutive section
intestinal gland; L, lumen; LP, lamina propria; SE, surface epithelium. Scale bars
118 Cell Reports 17, 114–124, September 27, 2016UGT2B7_i1 proteins to interact was further supported by co-IP
experiments and by their co-localization in the ER and may un-
derlie the induction in glucuronidation activity (Figures 5D and
5E). Untargeted metabolic profiling of the HEK293 and HepG2
cell models further revealed that the levels of a vast array of
cellular metabolites were significantly altered in cells overex-
pressing UGT2B7_i8 compared with control cells (Figure 5F;
Table S1). Despite the distinctive basal metabolomes of the kid-
ney and liver cell models, expression of UGT2B7_i8 induced a
remarkable accumulation of multiple amino acids in both cell
types, with the glutamine level being most altered. Most purines
and pyrimidines were reduced upon i8 expression in HEK cells,
whereas several glycolytic and tricarboxylic acid (TCA) cycle in-
termediateswere significantly reduced inHepG2 cells (Figure 5F;
Table S1). These alterations in numerous metabolites essential
for cell growth were associated with 3.5-fold enhanced adhesion
but 3.7-fold slower proliferation in HEK293 cells overexpressing
UGT2B7_i8 compared with control cells (Figure 5G). In support
of a specific effect of the UGT2B7_i8 protein, the adhesion and
proliferation of HEK293 cells overexpressing UGT2B7_i1 were
similar to the control cells despite higher expression of i1 than i8.
DISCUSSION
Our findings reveal large differences in the levels of naturally
occurring alternative mRNAs transcribed from UGT loci in major
metabolic tissues and demonstrate that these alternate tran-
scripts are expressed in a tissue-specific manner with remodel-
ing of the UGT transcriptome in cancer tissues. Among this large
collection of alternative UGT variants, expression of selected
alternately spliced isoforms with in-frame sequences was con-
firmed at the protein level in human tissues such as the liver
and colon. In cell-based assays, alternate UGT proteins were
shown to differentially regulate the glucuronidation pathway by
inhibiting or promoting the inactivation of drugs and hormones,
likely through protein-protein interactions. We also uncovered
that the alternate UGT isoforms have functions distinct from
the canonical glucuronidation function, and these appear to
broadly affect global metabolism, which results in changes in
cell behavior. These findings imply that this transcriptome diver-
sity expands the proteome and biological functions of human
UGTs, likely playing crucial roles in multiple cellular processes.
Our targeted CaptureSeq approach allowed high-resolution
quantitative evaluation of UGT expression in the liver, kidney,
and intestine/colon. A strength of our study is the mapping oftein levels of UGT1A1_i1, UGT1A1_i2, or both in the HEK293 cell models were
A antibody recognizing both isoforms. Bottom: densitometric quantification of
eatment. Data are presented as mean + SD.
1_i1, UGT1A1_i2, or both isoforms. In situ cell assays demonstrate that glu-
GT1A1_i2 (n = 2 independent assays in triplicate). UGT1A1_i2 did not catalyze
l. Data are presented as mean + SD. ***p < 0.001, Student’s t test.
pecific anti-i1 co-purifies UGT1A_i2. Lanes marked ‘‘ctr’’ served asmarkers for
5 cells. PDI is an ER marker, whereas Hoechst (H) labels nuclei. Fluorescence
for a comparison of co-localization with multiple specific subcellular markers,
s of normal human liver and colon tissues. H, hepatocytes; PV, portal vein; IG,
, 200 mm.
Figure 5. Functional Characterization of UGT2B7_i8
(A) Alternative splicing at the UGT2B7 locus. The canonical UGT2B7_v1 transcript excludes exon 2b (blue lines) and encodes the UGT2B7_i1 enzyme, whereas
UGT2B7_n4 includes exon 2b (green region, line, and boxed sequence) that extends the coding sequence to produce UGT2B7_i8. Anti-2B7_i8 was raised against
the underlined immunogenic peptide.
(B) Immunohistochemical investigation of i8 expression in normal liver tissues. Left: UGT2B7_i1, labeled by the commercial antibody against UGT2B7, is ex-
pressed predominantly in hepatocytes but not in hepatic arteries or bile ducts. Center: the purified anti-i8 specifically and strongly labels smooth muscle cells of
hepatic arteries, whereas hepatocytes are weakly labeled, and bile ducts are unlabeled. Right: labeling is impaired by preadsorption of anti-2B7_i8 with the
(legend continued on next page)
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RNA sequencing short reads on the exhaustive humanUGT tran-
scriptome established recently (Tourancheau et al., 2016), lead-
ing to a more precise assignment of reads to the appropriate
UGT loci and transcript reconstruction than previously possible.
This work revealed that alternative UGT mRNAs constitute an
appreciable proportion of the total UGT transcriptome in the sur-
veyed tissues, representing 19%–60% of all UGTmRNAs. In line
with this, there are many examples in the literature of protein
functional expansion created by AS, among which the human
tRNA synthetases and brain neurexins are remarkable recent ex-
amples (Lo et al., 2014; Treutlein et al., 2014). Our data further
indicate that UGT AS programs are constitutive in normal tis-
sues, implying that these events are associated with normal bio-
logical processes. This observation was also validated in an in-
dependent RNA-seq dataset not captured for UGT sequences
(Chhibber et al., 2016). These findings support a role for AS in
controlling coordinated cellular responses induced by small mol-
ecules and exposure to xenobiotics, including drugs of various
classes. Given the key role played by UGTs in cellular homeosta-
sis by inactivation of a variety of endogenous lipophilic cellular
constituents, one can envision that expression of alternative
UGTsmay be triggered by the cellular environment and/or stimuli
such as hormones and lipids (Dates et al., 2015; Hu et al., 2014).
Expression of alternative UGTs is also highly likely to be triggered
by exogenous stimuli and toxic xenobiotics that are common
substrates of UGTs (Hu et al., 2014). It remains unknownwhether
other enzymes involved in parallel cellular and drug metabolism
functions diversify their expression profiles and functional com-
plexity through splice variants. A recent study indicated that this
might be the case for a vast majority (>70%) of factors in drug-
related pathways, such as cytochromes P450 and other transfer-
ases (Chhibber et al., 2016). However, the regulation and func-
tional consequences of AS events for these clinically important
pharmacogenes remain undefined.
We estimate that only a small fraction of the UGT variants we
quantified may undergo nonsense-mediated mRNA decay ac-
cording to the 50-base pair (bp) rule (Popp and Maquat, 2013),
and, therefore, most observed UGT transcripts likely have the
potential to be translated. Multiple distinct features characterize
putative UGT isoforms, including truncated substrate or co-sub-
strate-binding domains and distinctive in-frame sequences. Weimmunogenic peptide prior to tissue labeling, demonstrating specificity of staining
tissues are shown. BD, bile ducts; HA, hepatic arteries. Scale bars, 200 mm.
(C) Metabolic alterations associated with the expression of UGT2B7_i8. HEK293
UGT2B7) were developed. UGT2B7_i8 has an apparent molecular mass of 62 k
analysis of the microsomal fractions (20 mg) from each cell model. L, human liv
the UGT2B7-specific substrate AZT is enhanced by co-expression of UGT2B7_i
assays; in triplicate). UGT2B7_i8 did not have glucuronidation activity with AZT as
as mean + SD. ***p < 0.001, Student’s t test.
(D) Interactions between UGT2B7_i8 and i1. IP of i8 from cell lysates of HEK293
purifies UGT2B7_i1.
(E) UGT2B7_i1 and i8 co-localize in the ER. Each UGT2B7 variant protein stably
intensity profiles are given for cross-sections (dashed lines). Scale bars, 10 mm.
(F) Cellular metabolic profiles reveal an important modulation of levels of amino ac
cell models. Data points for which the coefficient of variation exceeded 50% we
(G) UGT2B7_i8 enhances adhesion but reduces the proliferation rate of HEK293
index) (n = 2 independent assays in quadruplicate; significantly different for all tim
assays in triplicate), and doubling time was determined from real-time cell index d
See also Figures S3 and S4.
120 Cell Reports 17, 114–124, September 27, 2016provide evidence that AS may represent a potential mechanism
to modify canonical UGT function and to produce alternative
UGT isoforms with introduced domains and divergent functions.
Our findings with the UGT1A and UGT2B7 transcripts, which
encode, respectively, a shorter protein with an in-frame C-termi-
nal sequence and a longer protein with an internal peptide
sequence introduced, clearly support this notion. At the tran-
script level, UGT1A and UGT2B7 expression shows high interin-
dividual variability in the liver and kidney. Specific antibodies
raised against the peptide sequences not found in canonical
UGTs or any other known proteins labeled several human tissues
(IHC). Co-localization of alternate isoforms with canonical UGTs
in the same cell types, such as hepatocytes, was evident even
though relative abundance could not be deduced. According
to functional assays in intact proliferating cells, both UGT1A1_i2
and UGT2B7_i8 lack the ability to transfer a glucuronic acid moi-
ety to the typical substrates of the canonical enzymes and, there-
fore, would be enzymatically null. Alternate UGT1A_i2s contain
complete binding sites for both the substrate and co-substrate
and a C-terminal dilysine motif encoded by the new terminal
exon, but they lack the transmembrane-binding domain, which
likely affects membrane topology and conformation and, thus,
UGT activity. In contrast, UGT2B7_i8 contains all UGT domains
but also an internal 32-residue sequence that potentially disrupts
the coordination of co-substrate-to-substrate SN2 transfer of the
glucuronic acid for typical UGT2B7 substrates, such as AZT, as
observed in this study. Alternatively, this region may also poten-
tially adapt to a different set of substrates, changing substrate
specificity compared with the canonical UGT2B7 enzyme that
conjugates a wide variety of lipophilic metabolites and is
involved in the clearance of 25% of common medications
(Guillemette et al., 2014; Stingl et al., 2014). A larger set of sub-
strates, as well as co-substrates such as UDP-glucose, that are
metabolized byUGT2B7 in addition toUDPGA (Chau et al., 2014)
needs to be tested to determine whether the alternative UGT iso-
forms are truly enzymatically null.
When co-expressed with UGTs in human tissues and cells,
alternate UGTs either inhibited or activated cellular glucuronide
formation, significantly affecting inactivation of drugs and hor-
mones. To our knowledge, a UGT acting as an inducer/activator
of the glucuronidation pathway has not been reported before.with anti-2B7_i8. Representative images from consecutive sections of two liver
kidney and HepG2 liver cell models (expressing endogenous UGTs, including
Da, slightly larger than the UGT2B7_i1 enzyme (55 kDa), as expected, upon
er microsomes, as a positive control. In situ glucuronidation activity toward
1 and the i8 isoform in both cell models (HEK293, n = 4 assays; HepG2, n = 3
a substrate. Activity is normalized to the UGT2B7_i1 level. Data are presented
cells co-expressing UGT2B7_i1 and tagged UGT2B7_i8-V5 with anti-V5 co-
expressed in HEK293 cells co-localizes with the ER marker PDI. Fluorescence
ids and nucleotides induced by UGT2B7_i8 expression in HEK293 and HepG2
re omitted for clarity. Detailed metabolomics data are given in Table S1.
cells. Left: real-time cell adhesion was measured by electrical impedance (cell
e points). Right: proliferation was assessed by cell counts (n = 2 independent
ata. Data are presented as mean + SD. **p < 0.01, ***p < 0.001; Student’s t test.
Previous investigations by our group and others indicate that
UGTs form oligomeric complexes (Ishii et al., 2010; Operan˜a
and Tukey, 2007; Rouleau et al., 2013). The immunofluorescence
evidence of close proximity in the ER membrane and co-IP data
strongly suggest that the modulatory effects of the UGT1A and
UGT2B7 alternative isoforms are caused by direct protein-pro-
tein interactions with their cognate UGT enzymes, and perhaps
other UGTs, leading to a mixture of active and inactive com-
plexes (Ishii et al., 2010; Operan˜a and Tukey, 2007; Rouleau
et al., 2013). Given the enhanced stability of at least some
alternative isoforms relative to the canonical UGTs, as shown
for UGT1A1_i2, the effect of alternative isoforms on cellular
glucuronidation activity is likely greater than anticipated from
mRNA expression levels. We suggest that AS hampers or poten-
tiates canonical UGT functions. This likely helps to coordinate
and fine-tune cellular responses to numerous endogenous
and exogenous stimuli, with the potential to affect drug re-
sponses and disease development and progression, especially
tumorigenesis, given the altered ratio of alternative/canonical
variant expression and the large interindividual variability in their
expression.
Our functional investigations of the UGT2B7_i8 variant pro-
vide further evidence that alternative isoforms have extended
metabolic functions that affect global cell metabolism, suggest-
ing that they may be part of multi-enzyme complexes of a core
metabolic network. The biological relevance of a metabolic shift
induced by expression of UGT2B7_i8 alone warrants further
characterization, but our data also suggest that the glucuronida-
tion pathway and primary cell metabolism (e.g., amino acids
and nucleotides) are interrelated enzymatic processes. Whether
dimerization/oligomerization and/or glucuronidation of alterna-
tive endogenous substrates link the biological activity of these
isoforms with cell metabolism remains to be addressed.
Furthermore, UGT2B7_i8 expression is functionally linked to
modulation of cell adhesion and proliferation, supporting the
conclusion that UGTs substantially affect multiple cellular
processes.
Conclusions
This study provides a comprehensive quantitative portrait of he-
patic, renal, and gastrointestinal UGT transcriptomes and re-
veals the abundance of alternate UGT variants, which clearly
expand the UGT proteome. A first biological consequence of
altering the UGT transcriptome was emphasized by the func-
tional characterization of alternative isoforms with in-frame se-
quences introduced, which were found to antagonize or induce
cellular glucuronidation, thus affecting the inactivation of drugs
and sex hormones. This study also raises the exciting possibility
that different UGTsmay exhibit biological functions independent
of glucuronic acid transferase activity. Alternate isoform expres-
sion induced drastic shifts in multiple metabolic pathways and
modified cellular phenotypes, suggesting crosstalk between
various enzymatic pathways and UGTs that could serve to main-
tain cellular homeostasis and increase cell fitness. The broader
regulatory and functional relevance of such an extensive splicing
program remains to be fully characterized. We expect that this
work will enable the exploration of human UGT-mediated meta-
bolism and its potentially extended role in health and disease.EXPERIMENTAL PROCEDURES
RNA Samples, Sequencing, and mRNA Expression
UGT expression was characterized in normal tissue samples from nine liver,
nine kidney, and 15 intestine and colon samples as well as in samples from
nine kidney and nine intestine and colon tumor tissues of mixed-gender origin.
For each tissue, equivalent amounts of total RNA from at least three samples
were pooled, and three pools per tissue type were prepared and used for the
production of sequencing libraries. UGT sequences were enriched from
paired-end bar-coded cDNA libraries with UGT capture (Tourancheau et al.,
2016). The libraries were sequenced on an Illumina HiSeq 2500 system
(McGill University and Ge´nome Que´bec Innovation Center). Trimmed reads
were aligned with the splice-aware software TopHat2 on the UCSC hg19 refer-
ence genome with annotation provided by Illumina iGenome combined with
the complete annotated human UGT loci described recently by our group
(Tourancheau et al., 2016). The average normalized expression of replicates
is provided throughout the text. Detailed library construction, sequence anal-
ysis, and validation of UGT2B7_n4 expression by reverse transcription PCR
and Sanger sequencing are described in the Supplemental Experimental
Procedures.
Expression ofUGT1A andUGT2B7 variants was examined in 18 normal liver
and 18 normal kidney samples in the RNA-seq dataset from the Pharmacoge-
nomics Research Network (Chhibber et al., 2016) accessed from the GEO:
GSE70503. Alignment of reads on the complete human UGT transcriptome
and quantification using Cufflinks are described in the Supplemental Experi-
mental Procedures.
Cell Models
HT115 cells expressing endogenous UGT1A isoforms and HEK293 cell
models expressingmyc- or V5-tagged UGT1A1 isoforms have been described
previously (Bellemare et al., 2010a; Rouleau et al., 2014). The pool of HEK293
cells stably expressing UGT2B7_v1 was established by supplementing cell
culture media with G418 (Invitrogen, 1 mg/mL). The pool of HEK293 cells
co-expressing UGT2B7_v1 and UGT2B7_n4 (corresponding to the exon 2b
encoding transcript) was established by subsequent transfection of HEK-
2B7_v1 with the UGT2B7_n4 construct (with or without a V5 tag) and selection
with blasticidin (Wisent, 10 mg/mL). The HEK293 cell model expressing
UGT2B7_i1 and UGT2B7_i8-V5 was used only to demonstrate protein-protein
interactions by IP. HepG2 cells, which express UGT2B7_v1 endogenously but
not UGT2B7_n4, were transfected with the UGT2B7_n4 construct (without
a tag), and the pool was established with blasticidin selection. Control
HEK293 and HepG2 cells were produced by transfection with the parental
vectors and selection as above.
Analysis of Protein Expression
Antibodies
The UGT2B7 polyclonal antibody was from ProteinTech Group (16661-1-AP;
western blotting (WB), 1:5,000; IHC, 1:800; IF, 1:500), and the monoclonal
antibody was from Abcam (ab57685; IP, 1:100; note that ab57685 is sold as
an anti-UGT2B10 antibody, but it also recognizes UGT2B7 [Figure S5]). The
purified pan-UGT1A polyclonal antibody (RC-71; WB, 1:1,000), purified
UGT1A_i1 polyclonal antibody (9348; IHC and IF, 1:1,000; IP, 1:200), and
purified UGT1A_i2 antibody (4863; IHC, 1:1,000) have been described previ-
ously (Albert et al., 1999; Bellemare et al., 2011). UGT1A_i2 (4C5E7; IF,
1:100) and UGT2B7_i8 (IF and IHC, 1:1,000) antibodies were custom made
(GenScript). Anti-V5 (WB, 1:5,000) and anti-myc (clone 4A6; WB, 1:5,000)
were from Invitrogen and EMD Millipore, respectively. Cell compartment-spe-
cific antibodies used in IF were as follows: anti-58K Golgi protein (1:100,
ab27043, Abcam) and anti-protein disulfide isomerase (PDI) (1:100, ab2792,
Abcam) for the ER and anti-cytochrome c (1:300, 12963S, Cell Signaling
Technology) for the mitochondria. DNA was stained with Hoechst 33342
(1:1,500, Sigma) or DRAQ5 (1:2,000; Life Technologies). The production of
antibodies against variants is detailed in the Supplemental Experimental
Procedures.
mRNA and Protein Stability of UGT1A and UGT2B7
Cells were treated with 20 mg/mL cycloheximide for 0–16 hr and collected
at various time points as described previously (Turgeon et al., 2001). CellCell Reports 17, 114–124, September 27, 2016 121
homogenates (20 mg protein) prepared in PBS containing 0.5 mM DTT were
analyzed by WB with RC-71 (UGT1A) or anti-UGT2B7 from ProteinTech.
IF
Detection of endogenous UGT1A_i1 and _i2 in HT115 cells was as described
previously (Bellemare et al., 2010b). Stably expressed UGT2B7_i1 and
UGT2B7_i8 in the HEK cell models were detected with anti-2B7 16661-1-AP.
IHC
Paraffin-embedded tissue blocks were available for individual patients. The
institutional board approved the study, and written consent was given by all
patients concerning the use of their tissues for research purposes. Serial sec-
tions (5 mm) were deparaffinized, rehydrated, and processed using the IDetect
SuperStain horseradish peroxidase (HRP) polymer kit (Empire Genomics) with
an overnight incubation of tissues at 4C with primary antibodies. Control sec-
tions were incubated with the anti-UGT2B7_i8 preadsorbed for 3 hr at room
temperature with an excess of the immunogenic peptide (2 mM) to ascertain
labeling specificity.
IP
HEK293 UGT1A-tagged cell models were grown to confluency in 10-cm cul-
ture dishes, washed, scraped into 800 mL lysis buffer/dish, and immunoprecip-
itated as described in the Supplemental Experimental Procedures using anti-
UGT1A_i1 or control rabbit immunoglobulin G (IgG). For UGT2B7_i8 IP,
HEK293 cells grown in two 15-cm dishes were scraped and cross-linked
with 0.125% formaldehyde for 10 min at 37C and then quenched with
0.125 M glycine. Cells were collected by centrifugation prior to lysis in 1 mL
lysis buffer and immunoprecipitated as described in the Supplemental Exper-
imental Procedures.
MS-Coupled Multiple Reaction Monitoring
Tryptic digests of UGT2B7 immunoprecipitated from human liver S9 fractions
were analyzed by MS-coupled multiple reaction monitoring on a QTRAP 6500
hybrid triple quadrupole/linear ion trap mass spectrometer (Sciex). The
UGT2B7 signature peptide ADVWLIR and the UGT2B7_i8-specific peptide
LDSFNTGWINK were detected in tryptic digests of the immunoprecipitated
UGT2B7 samples, and peptide identity was confirmed by co-injection of isoto-
pically labeled [13C6,15N2]Lys and [13C6,15N4]Arg synthetic peptides.
Cell Adhesion and Proliferation
HEK293 and HepG2 cells (a pool of control cells or cells stably expressing
UGT2B7_n4) plated in E-view PET 16-well plates (10,000 cells/well, 4 repli-
cates/experiment, n = 3) were monitored in real time on an Xcelligence DP sys-
tem (ACEA Biosciences). Doubling time was determined with RTCA software
2.0 (ACEA Biosciences) using normalized cell index values between the 20-
and 45-hr time points. Alternatively, HEK293 and HepG2 cells were plated in
6-well plates (125,000 HEK cells/well, 100,000 HepG2 cells/well), incubated
for specified times, and counted with a TC-10 automated cell counter (Bio-
Rad) 48, 72, and 96 hr after plating. Cell media were replaced after the 48-hr
time point.
Metabolic Functions
In Situ Glucuronidation Assays
HEK293 and HepG2 cells (control cells or cells stably expressing UGT2B7_v1,
UGT2B7_n4, or both as stated in the figure legends) were seeded in 24-well
plates (HEK293, 80,000 cells/well; HepG2, 125,000 cells/well). Assays were
initiated 72 hr after seeding by replacing the culturemediumwith freshmedium
(1 mL/well) containing a labeled UGT substrate probe (for UGT1A1, 5 mM SN-
38 prepared by hydrolysis of irinotecan-HCl [McKesson] and/or 25 mM estra-
diol [Steraloids]; for UGT2B7, AZT [Sigma-Aldrich]). Cells were incubated for
4 hr, and the media were collected and stored at 20C until glucuronide
assessment by MS-based analysis as described previously (Be´langer et al.,
2009; Le´pine et al., 2004). Briefly, for zidovudine-glucuronide (AZT-G), the
culture media were diluted 1:3 with 25% aqueous methanol solution contain-
ing AZT-d3-G standard (Toronto Research Chemicals) prior to analysis as
described previously (Be´langer et al., 2009).
Untargeted Metabolomics Analysis
HEK293 and HepG2 cells (a stable pool of control cells or cells expressing
UGT2B7_n4) were plated in 10-cm culture dishes (1.5 million HEK cells/dish;
3.5 million HepG2 cells/dish) and grown for 96 hr with a change to fresh me-
dium after the first 48 hr. Cells were harvested by trypsinization, counted,
rinsed twice in ice-cold PBS, snap-frozen on dry ice, and stored at80C until122 Cell Reports 17, 114–124, September 27, 2016extraction for metabolomics analysis. Untargeted global metabolite profiling
was conducted on triplicate samples at the West Coast Metabolomics Center
(University of California at Davis) as described previously (Fiehn et al., 2008).
Relative quantification data provided as normalized peak heights were further
normalized for cell counts in each sample and expressed as fold change ratios
of mean metabolite levels in the cells expressing variant UGT2B7 versus con-
trol cells. Details about the data analysis are provided in the Supplemental
Experimental Procedures.
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